The Biggest Distributor May Be the Wrong Partner

The central decision

The distributor with the largest sales force, the broadest geographic reach or the most recognized name can still be the wrong partner for a specific healthcare product. Size can create capability, but it can also create portfolio congestion, diluted management attention and a mismatch between what the manufacturer needs and what the distributor is built to do.

The better question is not “Who is the biggest?” It is “Which partner gives this product the highest probability of becoming a priority, gaining the right access, executing the required work and learning fast enough to justify the next level of commitment?”

For European healthcare companies entering Saudi Arabia or the wider GCC, distributor selection is therefore not a procurement exercise. It is a strategic design decision that can shape regulatory coordination, channel access, launch quality, demand creation, cash conversion and the manufacturer’s future options.

Why size is such an attractive shortcut

Large distributors are easy to understand from the outside. Their footprint is visible. Their customer base appears reassuring. Their organizational scale can suggest lower execution risk. For a manufacturer with limited regional experience, those signals can feel like evidence that the difficult part of market entry has already been solved.

But those signals describe the distributor, not the fit between distributor and product. A partner can be excellent at serving a mature, high-volume portfolio and still be poorly configured for a product that needs category development, specialist education, institutional navigation, technical support or patient/practitioner adoption work.

The danger is subtle: the manufacturer can mistake access to a large platform for access to the market.

The Partner Fit Architecture

Optima Biomed evaluates distributor fit through six lenses. The aim is not to find a universally “best” distributor, but to identify the partner whose capabilities, incentives and operating model match the specific market-entry job that must be done.

A distributor can score highly on size and still fail on two or three of these dimensions. Conversely, a mid-sized partner can be strategically superior if the product is important to its portfolio, the relevant decision pathways are familiar, the required capabilities already exist and senior management is willing to invest attention.

Coverage is not the same as access

Manufacturers often ask how many hospitals, clinics, pharmacies or accounts a distributor covers. The more useful question is whether the distributor can reach the specific decision architecture that governs adoption of the product.

For one product, access may depend on institutional procurement and formulary processes. For another, it may depend on specialist physicians, technical departments, practitioners, private chains or a narrow group of high-value accounts. A large customer database does not prove strength at the exact points where the product has to win.

This distinction is particularly important in regulated healthcare categories. For example, current SFDA requirements for medical-device establishments distinguish activities such as importing and distribution and attach activity-specific licensing and operating requirements. That reinforces a broader commercial point: the partner must be assessed for the actual role it will perform, not merely for its corporate scale.

Portfolio congestion can turn strength into weakness

Large distributors often carry large portfolios. That can create cross-selling opportunities, but it can also create internal competition for sales time, management attention, launch resources and working capital. A new principal may enter the relationship believing it has selected a powerful route to market, only to discover that its product is commercially peripheral inside the partner organization.

The critical diligence question is therefore not simply “What can this distributor do?” but “What will this distributor actually do for us, at what priority, with which named resources, against which milestones?”

Do not confuse reputation with commitment

A strong market reputation reduces some forms of uncertainty. It does not automatically create commitment to a particular launch. Before appointment, manufacturers should test the proposed operating reality: who will own the business, what the first 90 and 180 days require, which accounts are genuinely addressable, what investment each side must make, what information will be shared and how performance will be reviewed.

This is where partner selection begins to overlap with governance design. But the distinction should remain clear: TEMP-005 is about choosing the partner before appointment. A separate Insight in this content wave will address why market entry can fail after the partner has already been appointed.

Five questions before shortlisting a distributor

• If this product represents only a small fraction of the distributor’s portfolio economics, what will make it a management priority?
• Which exact customer, stakeholder and access pathways must the partner influence - and where is there evidence of capability?
• What work is required beyond logistics and selling, and which of those capabilities are already operational?
• What commercial conditions could make the partnership unattractive to either side after the first year?
• If the first market-entry assumptions prove wrong, does the proposed structure preserve enough flexibility to change route, channel or scope?

A practical selection sequence

The strongest selection process starts with the market-entry job, not with a distributor list. Define the product’s access pathway, launch requirements, capability needs, investment profile and strategic constraints first. Only then should potential partners be screened and compared.

What the “right” partner actually means

The right distributor is not necessarily smaller. A large distributor may be the strongest fit when the product genuinely benefits from its infrastructure, customer access, systems and investment capacity. The point is that scale should be one input into the decision, not the decision rule itself.

Partner quality is product-specific and strategy-specific. The same distributor can be an excellent partner for one manufacturer and a weak partner for another because the required work, economics, portfolio priority and decision pathways are different.

The objective is not to minimize partner risk. It is to choose a partner whose strengths are aligned with the market-entry thesis and whose limitations are visible, governable and acceptable.